Back to Search Start Over

Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice

Authors :
Giannini E. G.
Bucci L.
Garuti F.
Brunacci M.
Lenzi B.
Valente M.
Caturelli E.
Cabibbo G.
Piscaglia F.
Virdone R.
Felder M.
Ciccarese F.
Foschi F. G.
Sacco R.
Svegliati Baroni G.
Farinati F.
Rapaccini G. L.
Olivani A.
Gasbarrini A.
Di Marco M.
Morisco F.
Zoli M.
Masotto A.
Borzio F.
Benvegnu L.
Marra F.
Colecchia A.
Nardone G.
Bernardi M.
Trevisani F
Olmi S
on behalf of Italian Liver Cancer (ITA. LI. CA) group
Giannini, E. G.
Bucci, L.
Garuti, F.
Brunacci, M.
Lenzi, B.
Valente, M.
Caturelli, E.
Cabibbo, G.
Piscaglia, F.
Virdone, R.
Felder, M.
Ciccarese, F.
Foschi, F. G.
Sacco, R.
Svegliati Baroni, G.
Farinati, F.
Rapaccini, G. L.
Olivani, A.
Gasbarrini, A.
Di Marco, M.
Morisco, F.
Zoli, M.
Masotto, A.
Borzio, F.
Benvegnu, L.
Marra, F.
Colecchia, A.
Nardone, G.
Bernardi, M.
Trevisani, F
Olmi, S
on behalf of Italian Liver Cancer (ITA. LI., CA) group
Giannini EG, Bucci L, Garuti F, Brunacci M, Lenzi B, Valente M, Caturelli E, Cabibbo G, Piscaglia F, Virdone R, Felder M, Ciccarese F, Foschi FG, Sacco R, Svegliati Baroni G, Farinati F, Rapaccini GL, Olivani A, Gasbarrini A, Di Marco M, Morisco F, Zoli M, Masotto A, Borzio F, Benvegnù L, Marra F, Colecchia A, Nardone G, Bernardi M, Trevisani F
Giannini, Edoardo G
Bucci, Laura
Garuti, Francesca
Brunacci, Matteo
Lenzi, Barbara
Valente, Matteo
Caturelli, Eugenio
Cabibbo, Giuseppe
Piscaglia, Fabio
Virdone, Roberto
Felder, Martina
Ciccarese, Francesca
Foschi, Francesco Giuseppe
Sacco, Rodolfo
Baroni, Gianluca Svegliati
Farinati, Fabio
Rapaccini, Gian Lodovico
Olivani, Andrea
Gasbarrini, Antonio
Di Marco, Maria
Morisco, Filomena
Zoli, Marco
Masotto, Alberto
Borzio, Franco
Benvegnù, Luisa
Marra, Fabio
Colecchia, Antonio
Nardone, Gerardo
Bernardi, Mauro
Trevisani, Franco
Publication Year :
2018

Abstract

The Barcelona Clinic Liver Cancer advanced stage (BCLC C) of hepatocellular carcinoma (HCC) includes a heterogeneous population, where sorafenib alone is the recommended treatment. In this study our aim was to assess treatment and overall survival (OS) of BCLC C patients sub-classified according to clinical features (Performance Status [PS], macro-vascular invasion [MVI], extra-hepatic spread [EHS] or MVI+EHS) determining their allocation to this stage. From the Italian Liver Cancer database, we analysed 835 consecutive BCLC C patients diagnosed between 2008 and 2014. Patients were sub-classified as: PS1 alone (n=385, 46.1%), PS2 alone (n=146, 17.5%), MVI (n=224, 26.8%), EHS (n=51, 6.1%) and MVI+EHS (n=29, 3.5%). MVI, EHS and MVI+EHS patients had larger and multifocal/massive HCCs and higher alpha-fetoprotein levels than PS1 and PS2 patients. Median OS significantly declined from PS1 (38.6 months) to PS2 (22.3 months), EHS (11.2 months), MVI (8.2 months) and MVI+EHS (3.1 months) (P

Details

Language :
English
Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....9a9229a7b49ea14b6ed47a849a9adbac